BNP Paribas Arbitrage SA decreased its position in shares of MiMedx Group Inc. (NASDAQ:MDXG) by 54.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,162 shares of the company’s stock after selling 17,071 shares during the period. BNP Paribas Arbitrage SA’s holdings in MiMedx Group were worth $122,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mason Street Advisors LLC purchased a new stake in MiMedx Group during the second quarter worth $156,000. Royal Bank of Canada raised its stake in MiMedx Group by 808.5% in the second quarter. Royal Bank of Canada now owns 170,171 shares of the company’s stock worth $1,358,000 after buying an additional 151,440 shares in the last quarter. Investment Centers of America Inc. raised its stake in MiMedx Group by 60.3% in the second quarter. Investment Centers of America Inc. now owns 47,850 shares of the company’s stock worth $382,000 after buying an additional 18,000 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in MiMedx Group by 2.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 357,478 shares of the company’s stock worth $2,853,000 after buying an additional 7,680 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in MiMedx Group during the second quarter worth $1,197,000. 44.32% of the stock is owned by institutional investors.
Shares of MiMedx Group Inc. (NASDAQ:MDXG) opened at 8.38 on Friday. MiMedx Group Inc. has a 12 month low of $6.64 and a 12 month high of $9.90. The company has a market capitalization of $922.15 million, a price-to-earnings ratio of 39.72 and a beta of 0.70. The company’s 50-day moving average is $8.38 and its 200 day moving average is $7.92.
MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Tuesday, July 26th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by $0.02. The firm had revenue of $57 million for the quarter, compared to analyst estimates of $56.49 million. MiMedx Group had a return on equity of 22.16% and a net margin of 10.92%. MiMedx Group’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 EPS. On average, equities research analysts anticipate that MiMedx Group Inc. will post $0.22 earnings per share for the current year.
A number of analysts have recently commented on MDXG shares. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price target on shares of MiMedx Group in a research note on Wednesday, August 31st. Brean Capital reiterated a “buy” rating on shares of MiMedx Group in a research note on Wednesday, June 29th. Finally, Zacks Investment Research upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. MiMedx Group has a consensus rating of “Buy” and an average target price of $10.89.
In other news, insider William Charles Taylor sold 20,400 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $7.55, for a total transaction of $154,020.00. Following the transaction, the insider now owns 566,566 shares in the company, valued at approximately $4,277,573.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 12.30% of the company’s stock.
MiMedx Group Company Profile
MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group Inc. (NASDAQ:MDXG).
Receive News & Ratings for MiMedx Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.